We are pleased to announce that CUROGEN signed a research agreement with the Korea Drug Development Fund (KDDF) on December 3rd for the pre-clinical validation of CR-C003, a first-in-class drug candidate for the treatment of inflammatory bowel disease.

Through this two-year collaboration, CUROGEN will receive comprehensive R&D funding and technical advisory support from the KDDF consortium throughout the entire preclinical phase. The project will focus on efficacy and toxicity evaluation, formulation development, pharmacokinetic (PK) studies, and the establishment of a pilot-scale API manufacturing process.

Chang-woo Lee, CEO, and Hyunsoo Kim, Head of R&D, represented CUROGEN at the signing ceremony.

This agreement marks CUROGEN’s fifth national grant from KDDF, underscoring our continued commitment to advancing innovative drug development and strengthening Korea’s pharmaceutical competitiveness on the global stage.